中药降脂1号对高脂血症大鼠抗氧化作用实验研究

目的：探讨中药降脂1号对高脂血症Wistar大鼠的抗氧化作用,方法：通过高脂饮食诱导建立高脂血症动物模型,分别用不同剂量的中药降脂1号与西药（力平之,微粒化非诺贝特胶囊）给高脂血症动物模型连续28d灌胃后,检测高脂血症动物的血脂指标和肝脏抗氧化指标,结果：用药28d后,肝脏M DA水平降低（P〈0.05）,肝脏SOD活力提高,具有保护肝脏功能;中药降脂1号与西药对照组比较,更能促进肝组织形态的恢复。结论：中药降脂1号对高脂血症大鼠有明显抗氧化作用,可以升高SOD活力,降低M DA,降低肝脏脂质过氧化水平,提高肝脏抗氧化能力。     

中药降脂1号对高脂血症大鼠血脂的影响

目的:探讨中药降脂1号对高脂血症Wistar大鼠的降血脂作用.方法:通过高脂饮食诱导建立高脂血症动物模型,分别用不同剂量的中药降脂1号与西药(力平之,微粒化非诺贝特胶囊)给高脂血症动物模型连续28d灌胃后,检测高脂血症动物的血脂指标.结果:模型组与中药大剂量组,小剂量组,阳性药物对照组比较TC、TG 、LDL-C水平均明显下降; HDL-C水平升高.结论:中药降脂1号能明显降低高脂血症大鼠的血清TC、TG、LDL-C水平,提高HDL-C水平作用.     

基于转录组学技术研究泽泻汤对高脂血症大鼠的降脂作用机制

高脂血症是一种脂质代谢紊乱,其特征是血液循环中脂质水平升高.高脂血症一直与心血管事件和代谢综合征相关疾病的发展有关.泽泻汤(ARD)是著名的中药处方,长期以来被用于治疗眩晕症,这是高脂血症患者的一种症状.在本研究中,我们旨在转录水平上研究ARD对高脂血症大鼠的降脂活性和潜在分子机制.同时应用RNA测序和转录组分析,包括...     

姜黄素纳米乳的制备和药动学及药效学研究

目的 探究姜黄素纳米乳在大鼠体内的药动学特性和对大鼠高脂血症的药效作用。方法 建立大鼠血浆中姜黄素的高效液相色谱-质谱联用（HPLC-MS）含量测定方法,考察纳米乳的体内药动学过程。建立SD大鼠高脂血症动物模型,初步考察姜黄素纳米乳对高脂饮食诱导的大鼠高脂血症的药效作用。结果 体内药动学研究结果表明,以姜黄素原料药为参比制剂,姜黄素纳米乳的相对生物利用度为313.47%;以市售片剂为参比制剂,姜黄素纳米乳的相对生物利用度为279.52%。纳米乳组的Cmax为原料药组的201.48%,为片剂组的193.02%,且比原料药组及片剂组具有更高的MRT值（为原料药组的183.52%,是片剂组的154.21%）。药效学研究结果表明姜黄素纳米乳口服给药系统能显著降低模型大鼠的血清总胆固醇（TC）、低密度脂蛋白（LDLc）,缓解高脂饮食给模型大鼠造成的肝脏脂质沉积及肝损伤。结论 姜黄素纳米乳口服给药系统能够有效改善姜黄素的生物利用度,具有良好的降血脂作用,并能够控制高脂血症大鼠体重增长和改善由脂质代谢紊乱造成的肝脏系数变化。     

血脂康治疗原发性高脂血症的疗效观察

大量研究证实,高脂血症与动脉硬化及冠心病发病有密切联系,对高胆固醇血症的治疗在冠心病的一级预防和二级预防中起着重要作用。因此,如何发挥中医中药的优势,探索使用中药纠正脂质代谢紊乱,显得十分重要。作者选用北大维信生物科技有限公司应用高科技生物技术从特制红曲中提炼精制而成的血脂康胶囊治疗30例高脂血症患者,对降脂疗效进行了临床观察。本文对此作一报道。 1 资料和方法 1.1 病例选择 选择自本院门诊(未经治疗或曾用其它降脂药物治疗     

中药降脂方对高脂血症家兔红细胞膜成分的影响

目的：观察中药降脂方对红细胞膜胆固醇与磷脂比值（Ch/Pl)变化。方法：心高脂饲料造成家兔实验性高血脂症模型。酶法测定胆固醇（Ch)，用分光光度法测定磷脂（P1），实验设空白对照组，模型组，中药组和多烯康组。分别观察中药降脂方的降脂作用和对红细胞膜成分的影响。结果：中药降脂方对高脂血症家兔有较好的降脂作用，红细胞膜Ch/Pl也有所下降，结论：这项指标的建立对于临床高血脂，高血压，冠心病等疾病的监测和药物疗效的考察提供参考价值。     

鸡血藤降低高脂血症大鼠血脂及抗脂质过氧化的作用研究

目的研究鸡血藤对高脂血症大鼠血脂及抗脂质过氧化的作用.方法观察鸡血藤对高脂血症模型大鼠的降脂作用,同时还观察了其对血浆超氧化物歧化酶(SOD)和脂质过氧化产物(LPO)含量的影响.结果鸡血藤可降低高脂血症大鼠的血浆SOD和LPO;还可降低血清胆固醇(CH)和甘油三脂(TG);并升高高脂血症大鼠的高密度脂蛋白(HDL),降低低密度脂蛋白.结论提示鸡血藤具有降低血脂和抗脂质过氧化的双重作用.     

脂质组学在疾病生物标记物研究应用现状

脂质组学通过研究脂质的结构和功能及其在体内的代谢变化,明确其对疾病诊断和治疗的作用,以期提高疾病风险预测的能力。常用脂质组学分析方法包括直接质谱注入法（鸟枪法）、色谱质谱联用法和核磁共振法等。脂质组学在疾病早期诊断、生物标志物的发现、新药研发以及系统研究方面都发挥了很大作用。本文旨在介绍脂质组学在疾病生物标志物发现中的应用及其研究方法。     

降脂康对大鼠实验性高血脂症的降脂作用

目的:研究降脂康对高脂血症大鼠的影响,为临床应用提供实验依据。方法:测定高脂饲料致高脂血症大鼠的血清TG、TC、LDL-C、HDL-C。结果:降脂康能明显降低高脂血症大鼠血清胆固醇、甘油三酯及低密度脂蛋白的含量。结论:降脂康给药能明显降低高脂血症大鼠的血脂水平,可能对高脂血症和动脉粥样硬化症有防治作用。     

自制中药降脂散治疗高脂血症的疗效研究

目的研究自制中药降脂散治疗高脂血症的效果。方法收集临床上高脂血症的病例资料,按照服用自制中药降脂散和立普妥分为两组,分别于用药前后检测血胆固醇(TC)、三酰甘油(TG)、高密度脂肪酸(HDL)、低密度脂肪酸(LDL)、极低密度脂肪酸(VLDL)水平,并用SPSS18.0分析所得数据。结果自制中药降脂散能降低血TC、TG、LDL、VLDL水平、升高HDL水平,且产生的不良反应比立普妥少。结论自制中药降脂散有显著的降脂疗效、不良反应少,值得在临床应用中推广。     

Application of comprehensive lipidomics to biomarker research on adverse drug reactions

Lipidomics is a relatively new field of omics that focuses on lipids, one of the major categories of metabolites. Owing to their various functions, lipids are considered suitable targets for biomarker development; in addition, lipidomics analysis of adverse drug reactions (ADRs) has been conducted recently. In this review, I have summarized information on comprehensive lipidomics, which involves the analysis of global lipids in a non-targeted manner. Mass spectrometry-based platforms are currently the dominant lipidomics platform owing to their versatile features. I have also summarized the application of lipidomics in biomarker research on ADRs caused by therapeutic drugs in humans and rodents. Additionally, general concerns in and emerging approaches of lipidomics research on ADR have been highlighted. Although biomarkers identified using the lipidomics analysis of ADRs have not been qualified, reported candidates will be evaluated for clinical application. In addition, novel biomarker candidates will be developed via classical and new approaches exemplified in this review.     

中药干预高脂血症相关信号通路的研究进展

高脂血症是因多种原因导致脂质代谢紊乱的一种病理状态,可引起动脉粥样硬化等多种疾病的发生,严重影响患者的生活质量。目前化学药治疗存在不良反应大、耐药等缺点。而中药用于治疗高脂血症的历史悠久,临床经验丰富,且以不良反应少、用药依从性好的优点成为近几年研究的热点。通过查阅分析国内外有关中药干预高脂血症信号通路的文献,归纳总结出6条中药干预高脂血症相关信号通路,分别为过氧化物酶体增殖物激活受体（PPAR）信号通路、腺苷酸激活蛋白激酶（AMPK）信号通路、环磷酸腺苷（cAMP）信号通路、脂肪细胞因子（Adipocytokine）信号通路、法尼酯衍生物X受体（FXR）-小异二聚体伴侣（SHP）信号通路及磷脂酰肌醇-3-激酶（PI3K）-丝氨酸/蛋白激酶B（Akt）信号通路,以期为治疗高脂血症的药物研发提供参考。     

The emerging role of plasma lipidomics in cardiovascular drug discovery

INTRODUCTION: With the rising global incidence of cardiovascular disease, the challenge for the pharmaceutical industry is to identify novel biomarkers that will allow not only for the development of the next generation of cardiometabolic therapeutics, but also to serve as a sensitive mechanism to monitor and predict drug efficacy and potential toxicity. The advent of an 'omics' (systems biological) approach has vast implications for future disease treatment and prevention. Lipidomics is the latest addition to the 'omics' family and is rapidly gaining attention due to the technological improvements in mass spectrometry, allowing for the characterization of large number of lipids (and their respective subclasses) in a short amount of time with relatively minimal preparation. AREAS COVERED: The authors discuss the various techniques involved in plasma lipidomics as well as outline the role that lipidomics will play in phenotyping disease processes and corresponding therapeutic strategies. The article was formed through comprehensive Medline search of relevant publications in this area. EXPERT OPINION: Despite the wealth of data that will emerge regarding the various lipid-molecular interactions and the functions of lipids within cells, a major challenge will be the parallel emergence of novel bioinformatics platforms in order to integrate this enormous data set with information generated from the emerging fields of genomics and proteomic analysis. Despite these challenges, lipidomics is likely to result in the reclassification of diseases from a molecular perspective and play a key role the eventuation of personalized medicine.     

中蒙药降血脂作用研究进展

高血脂症是目前严重影响人类健康的一类疾病,因而,开发有效的降脂药物成为了全球热点。由于中蒙药药物资源丰富,不良反应较少,疗效比较确切,降血脂作用途径种类较多,所以,利用民族医药治疗高血脂症是现在较为有效的方法。本文通过阐述高发病机制和中蒙药目前降血脂作用的研究进展,充分体现了中蒙药的特色,为中蒙药降血脂在临床上的进一步应用和开发提供了参考。     

Lipid mediator informatics-lipidomics: Novel pathways in mapping resolution

Lipidomics, the systematic decoding of lipid-based information in biosystems, is composed of identifying and profiling lipids and lipid-derived mediators. As currently practiced, lipidomics can be subdivided into architecture/membrane lipidomics and mediator lipidomics. The mapping of structural components and their relation to cell activation as well as generation of potent lipid mediators and networks involves a mass spectrometry-computational approach so that interrelationships and complex mediator networks important for cell homeostasis can be appreciated. Cell membranes are composed of a bilayer that contains phospholipids, fatty acids, integral membrane proteins, membrane-associated proteins, sphingolipids, and so on. The membrane composition of many cell types has been established. The components' organization and effect on cell function remains to be established, however, and is a quest for lipidomics. Here, we review liquid chromatography tandem mass spectrometry-based lipidomic analyses to address bioactive lipid mediators in signaling pathways and the roles of lipid-derived mediators in resolution of inflammation.     

中西医结合治疗高脂血症120例临床观察

目的观察中西医结合治疗高脂血症的临床疗效。方法将患者随机分为两组,治疗组120例采用中药结合辛伐他汀治疗,对照组100例单纯采用辛伐他汀治疗。结果两组均能显著降低血浆总胆固醇（TC）、甘油三脂（TG）、低密度脂蛋白胆固醇（LDL—C）,升高高密度脂蛋白胆固醇（HDL—C）,但治疗组与对照组比较差异有统计学意义（P〈0．05）。结论中西医结合治疗高脂血症疗效优于单纯西药降脂治疗。     

Lipids and lipidomics in brain injury and diseases

Lipidomics is systems-level analysis and characterization of lipids and their interacting moieties. The amount of information in the genomic and proteomic fields is greater than that in the lipidomics field, because of the complex nature of lipids and the limitations of tools for analysis. The main innovation during recent years that has spurred advances in lipid analysis has been the development of new mass spectroscopic techniques, particularly the "soft ionization" techniques electrospray ionization and matrix-assisted laser desorption/ionization. Lipid metabolism may be of particular importance for the central nervous system, as it has a high concentration of lipids. The crucial role of lipids in cell signaling and tissue physiology is demonstrated by the many neurological disorders, including bipolar disorders and schizophrenia, and neurodegenerative diseases such as Alzheimer's, Parkinson's, and Niemann-Pick diseases, that involve deregulated lipid metabolism. Altered lipid metabolism is also believed to contribute to cerebral ischemic (stroke) injury. Lipidomics will provide a molecular signature to a certain pathway or a disease condition. Lipidomic analyses (characterizing complex mixtures of lipids and identifying previously unknown changes in lipid metabolism) together with RNA silencing, using small interfering RNA (siRNA), may provide powerful tools to elucidate the specific roles of lipid intermediates in cell signaling and open new opportunities for drug development.     

Lipidomics in drug and biomarker development

Lipidomics is an emerging field in biomedical research. It aims at systems scale detection, characterisation and quantification of lipids. Lipidomics is developing as an independent discipline at the interface of lipid biology, technology and medicine. Technological advancements, most notably in liquid chromatography and mass spectrometry, allow sensitive and highly selective analysis of lipids with diverse chemical composition and in complex mixtures. Comparative analysis of such lipid profiles, which stem from two physiologically linked conditions is particularly powerful for applications in drug and biomarker development. First, it leads to the identification of pathways related to lipid metabolism. Second, multiparameter lipid biomarkers will provide better diagnostics in preclinical trials using model organisms and in clinical presentations in humans.     

The emerging role of plasma lipidomics in cardiovascular drug discovery

Introduction: With the rising global incidence of cardiovascular disease, the challenge for the pharmaceutical industry is to identify novel biomarkers that will allow not only for the development of the next generation of cardiometabolic therapeutics, but also to serve as a sensitive mechanism to monitor and predict drug efficacy and potential toxicity. The advent of an ‘omics’ (systems biological) approach has vast implications for future disease treatment and prevention. Lipidomics is the latest addition to the ‘omics’ family and is rapidly gaining attention due to the technological improvements in mass spectrometry, allowing for the characterization of large number of lipids (and their respective subclasses) in a short amount of time with relatively minimal preparation.

Areas covered: The authors discuss the various techniques involved in plasma lipidomics as well as outline the role that lipidomics will play in phenotyping disease processes and corresponding therapeutic strategies. The article was formed through comprehensive Medline search of relevant publications in this area.

Expert opinion: Despite the wealth of data that will emerge regarding the various lipid–molecular interactions and the functions of lipids within cells, a major challenge will be the parallel emergence of novel bioinformatics platforms in order to integrate this enormous data set with information generated from the emerging fields of genomics and proteomic analysis. Despite these challenges, lipidomics is likely to result in the reclassification of diseases from a molecular perspective and play a key role the eventuation of personalized medicine.     

基于网络药理学分析荷丹片与他汀类药物的协同降脂作用

目的 采用网络药理学的方法,筛选荷丹片组方的活性成分和与高脂血症疾病相关的作用靶点,通过生物过程与通路富集预测其作用机制,从而获得荷丹片与他汀类药物协同作用的依据.方法 利用中药系统药理学分析平台(TCMSP,https://tcmspw.com/tcmsp.php)等数据库及文献筛选荷丹片的活性成分及靶点,利用Gee...